pipette
ENEnglish

Cervical lymph node B cell subset resists depletion and sustains lytic Epstein Barr-virus signature in patients with multiple sclerosis

Y. K. Babal, J. Sarkkinen, E. Ahvenainen, A. Susi, M. Saarela, G. Kurdo, S. M. Laakso

PreprintUso en el mundo real

En palabras de los autores

B cells have arisen as key in multiple sclerosis (MS) pathogenesis by the high efficacy of B cell depleting CD20 monoclonal antibodies and by the identification of Epstein-Barr virus (EBV) as a prerequisite factor. We previously demonstrated an expansion of memory and double negative (DN) B cells in the deep cervical lymph nodes (dcLNs) of newly diagnosed patients with MS (pwMS), with DN B cells showing a molecular signature consistent with lytic EBV infection. Effect of anti-CD20 therapies for pwMS require sustained administration, which led us to hypothesize that incomplete effects on the dcLNs, a natural site for lymphocyte priming towards the central nervous system (CNS), might be sustaining the pathology. Using single-cell transcriptomics and paired sampling, we characterized the effects of anti-CD20 therapies on dcLNs compared to circulation and to other therapies. We observed switched (SM) and unswitched (USM) memory B cells to be depleted uniquely by anti-CD20 in both dcLNs and circulation, whereas DN B cells of the dcLNs were not. Moreover, EBV lytic signature was retained in DN B cells during anti-CD20, and using clonal trajectory we saw that the DN B cells continued to contribute to the plasmablast differentiation within dcLNs. EBV targeting of expanded memory CD8 T cells, as well as CD8 T cell exhaustion, were retained during anti-CD20 therapy within the dcLNs. Our findings suggest a sustained, EBV-driven process in pwMS during anti-CD20 in the CNS-targeting priming dcLNs, with therapeutic implications to be investigated further.

Resultado principalLimitación que admiten los autores

Apareció: jueves, 29 de octubre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.10.25.26366311